Skip to main content
All lobbying filings

THE UNITED STATES PHARMACOPEIAL CONVENTION

THE UNITED STATES PHARMACOPEIAL CONVENTION filed a Q2 report for THE UNITED STATES PHARMACOPEIAL CONVENTION on July 21, 2025.

Lobbying for THE UNITED STATES PHARMACOPEIAL CONVENTION

All filings by THE UNITED STATES PHARMACOPEIAL CONVENTION · Everything THE UNITED STATES PHARMACOPEIAL CONVENTION has reported

 Filing · LD-2 quarterly report Q2 report
Reporting period
2nd Quarter 2025
Apr 1 - June 30 · Posted Jul 21, 2025
Expenses
$110,000
What this organization spent lobbying with its own staff. Reported using IRS section 6033(b)(8) definitions (method B): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
Maryland

Official filing document

 Lobbyists on this filing 1
  • TIMOTHY J CASEY New on this filing
    Previously held: Legislative Assistant, Rep. John Tierney; Legislative Correspondent, Sen. Tom Carper.

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

 Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 1
Health Issues

S. 1784 - Mapping America's Pharmaceutical Supply (MAPS) Act; H.R. 4191: Provisions regarding supply chain resilience. Issues regarding drug shortages and pharmaceutical supply chain resilience.

 Bills named in this filing 2

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem